Covered, raised, and inside its leverage target. The board raised the quarterly dividend to $0.94 from $0.92 on August 7, 2026, payable November 6, 2026 — and second-quarter normalized FFO of $1.19 a share covers that new rate at about a 79% payout. Normalized funds available for distribution rose to $61.6 million in the quarter from $56.0 million a year earlier, and first-half normalized FFO of $2.42 was up 2.1% year over year. Leverage is squarely inside policy: consolidated net debt to adjusted EBITDA was 4.1× at June 30, 2026, within the company's 3.5× to 4.5× target range, after it repaid a $125 million term loan at maturity. The quarter's GAAP net income of $1.15 a share included a $22 million real-estate sale gain, so the FFO figures, not the headline earnings, are what carry this grade.
Key risk: Senior-housing operator exposure as NHI shifts toward operating (SHOP) properties — management aims for SHOP to reach 40% to 50% of the portfolio over about three years, which trades predictable triple-net rent for operating results. If SHOP occupancy or margins slip, the steadiness this grade rests on weakens.
Changes if: Normalized FFO falls below the $0.94 quarterly dividend on a sustained basis, net debt to adjusted EBITDA moves outside the 3.5× to 4.5× target range, or the dividend is held flat after a raise — any of those would reopen a payout that currently looks comfortable.
- ✓FFO coverage check: Second-quarter normalized FFO of $1.19 a share covers the raised $0.94 quarterly dividend at about 79%, and normalized FAD rose to $61.6 million from $56.0 million a year earlier.
- ✓Leverage check: Consolidated net debt to adjusted EBITDA of 4.1× at June 30, 2026 sits inside the company's 3.5× to 4.5× target range, with a $125 million term loan repaid at maturity in the quarter.
- !Growth check: The dividend was raised $0.92 to $0.94 in August 2026 and first-half normalized FFO rose 2.1% year over year — though second-quarter normalized FFO per share alone dipped 2.5% to $1.19, so growth is modest, not rapid.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.